Alpha 2.0
Login Register
» Authors » Martina Oneko

Martina Oneko

Explore the profile of Martina Oneko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 1872
Followers 0
Related Specialties
General Medicine
Infectious Diseases
Microbiology
Top 10 Co-Authors
Simon Kariuki
Mary J Hamel
Kephas Otieno
Laurence Slutsker
Innocent Valea
Tsiri Agbenyega
Halidou Tinto
Daniel Ansong
Samuel Adjei
Walter Otieno
Published In
Malar J
Lancet Infect Dis
Clin Infect Dis
Vaccine
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine
Senkpeil L, Bhardwaj J, Little M, Holla P, Upadhye A, Fusco E, et al.
JCI Insight . 2024 Apr; 9(11). PMID: 38687615
A systems analysis was conducted to determine the potential molecular mechanisms underlying differential immunogenicity and protective efficacy results of a clinical trial of the radiation-attenuated whole-sporozoite PfSPZ vaccine in African...
2.
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Westercamp N, Osei-Tutu L, Schuerman L, Kariuki S, Bollaerts A, Lee C, et al.
J Infect Dis . 2024 Mar; 230(2):e486-e495. PMID: 38438123
Background: The RTS,S/AS01E (RTS,S) malaria vaccine is recommended for children in malaria endemic areas. This phase 2b trial evaluates RTS,S fractional- and full-dose regimens in Ghana and Kenya. Methods: In...
3.
Sporozoite immunization: innovative translational science to support the fight against malaria
Richie T, Church L, Murshedkar T, Billingsley P, James E, Chen M, et al.
Expert Rev Vaccines . 2023 Aug; 22(1):964-1007. PMID: 37571809
Introduction: Malaria, a devastating febrile illness caused by protozoan parasites, sickened 247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in sub-Saharan Africa. A highly effective vaccine...
4.
Post-Discharge Risk of Mortality in Children under 5 Years of Age in Western Kenya: A Retrospective Cohort Study
Kwambai T, Kariuki S, Smit M, Nevitt S, Onyango E, Oneko M, et al.
Am J Trop Med Hyg . 2023 Aug; 109(3):704-712. PMID: 37549893
Limited evidence suggests that children in sub-Saharan Africa hospitalized with all-cause severe anemia or severe acute malnutrition (SAM) are at high risk of dying in the first few months after...
5.
Fetal sex and risk of pregnancy-associated malaria in Plasmodium falciparum-endemic regions: a meta-analysis
Unger H, Hadiprodjo A, Gutman J, Briand V, Fievet N, Valea I, et al.
Sci Rep . 2023 Jun; 13(1):10310. PMID: 37365258
In areas of moderate to intense Plasmodium falciparum transmission, malaria in pregnancy remains a significant cause of low birth weight, stillbirth, and severe anaemia. Previously, fetal sex has been identified...
6.
Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy
Kc N, Church L, Riyahi P, Chakravarty S, Seder R, Epstein J, et al.
Front Immunol . 2022 Nov; 13:1006716. PMID: 36389797
Background: While prior research has shown differences in the risk of malaria infection and sickness between males and females, little is known about sex differences in vaccine-induced immunity to malaria....
7.
Efficacy of RTS,S/AS01 malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Samuels A, Ansong D, Kariuki S, Adjei S, Bollaerts A, Ockenhouse C, et al.
Lancet Infect Dis . 2022 Jun; 22(9):1329-1342. PMID: 35753316
Background: Controlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens...
8.
Assessing the safety, impact and effectiveness of RTS,S/AS01 malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
Praet N, Asante K, Bozonnat M, Akite E, Ansah P, Baril L, et al.
Malar J . 2022 Apr; 21(1):132. PMID: 35468801
Background: Following a 30-year development process, RTS,S/AS01 (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating...
9.
The burden of influenza among Kenyan pregnant and postpartum women and their infants, 2015-2020
Otieno N, Nyawanda B, McMorrow M, Oneko M, Omollo D, Lidechi S, et al.
Influenza Other Respir Viruses . 2022 Jan; 16(3):452-461. PMID: 35066993
Background: In tropical Africa, data about influenza-associated illness burden are needed to assess potential benefits of influenza vaccination among pregnant women. We estimated the incidence of influenza among pregnant women...
10.
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
Oneko M, Steinhardt L, Yego R, Wiegand R, Swanson P, Kc N, et al.
Nat Med . 2021 Sep; 27(9):1636-1645. PMID: 34518679
The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccine provides protection against P. falciparum infection in malaria-naïve adults. Preclinical studies show that T cell-mediated immunity is required for protection and is readily...